Aetna Transvaginal Ultrasound Coverage Update

inv-01: Medical Necessity Indications

Covered when any of the following indications are present (medical necessity):

Medical necessity indications: 1. Assessment of a pelvic mass (e.g., adenomyosis, cancer, cyst, and fibroid); 2. Diagnosis of bowel endometriosis; 3. Diagnosis of ectopic pregnancy; 4. Diagnosis of vasa previa; 5. Evaluation of abnormal uterine bleeding; 6. Evaluation of congenital uterine anomalies; 7. Evaluation of infertility; 8. Evaluation of pelvic pain of suspected gynecologic origin; 9. Evaluation for sequelae of pelvic infection (e.g., abscess, and hydrosalpinx); 10. Evaluation of women with new symptoms (bloating, difficulty eating or feeling full quickly, pelvic or abdominal pain, or urinary frequency and urgency) that have persisted for 3 or more weeks, and the clinician has performed a pelvic and rectal examination and suspects ovarian cancer; 11. Evaluation of women with post-menopausal bleeding; 12. Guidance during embryo transfer; 13. Monitoring natural or stimulated follicular development during infertility therapy; 14. Monitoring of women with Lynch II syndrome or BRCA mutation for ovarian cancer (Doppler mode is considered not medically necessary for this indication); 15. Verifying position of intrauterine device if IUD string is not visible or if there is suspicion that IUD is malpositioned.

List reflects policy's enumerated indications.

inv-02: Experimental/Investigational

Experimental / investigational (not covered) situations:

Experimental and Investigational: Transvaginal ultrasonography (TV-US) is considered experimental and investigational for population screening for endometrial cancer, ovarian cancer, or other gynecologic cancers because of insufficient evidence of effectiveness of these approaches for cancer screening.

Policy explicitly states screening for gynecologic cancers is investigational.

inv-03: Postmenopausal bleeding — initial evaluation

Use of TV‑US in evaluation of postmenopausal bleeding

Postmenopausal bleeding triage: Either endometrial biopsy OR transvaginal ultrasound is an acceptable initial evaluation; performance of both tests is not required. When TV‑US shows an endometrial thickness ≤ 4 mm, endometrial sampling is not required. If ultrasound assessment is inadequate or bleeding persists despite negative initial evaluations, additional assessment (such as endometrial sampling) is usually indicated.endometrial thickness <= 4 mm

Initial evaluation does not require both tests

inv-04: Ovarian cancer screening

Population screening for ovarian cancer

Screening in asymptomatic women: Randomized trials and systematic reviews have not demonstrated a mortality benefit for routine population-based screening for ovarian cancer using TV‑US alone or combined with CA‑125. Screening is associated with high rates of repeat testing and surgeries per detected cancer (e.g., PLCO reported ~19.5 surgeries per screen-detected cancer) and many screen-detected cancers are late stage; routine population screening is not supported by current evidence.

Specific studies referenced include PLCO and UKCTOCS.

inv-05: IUD position

IUD position confirmation

IUD position assessment: Clinical evaluation has high negative predictive value for detecting abnormal IUD position and routine TV‑US is not indicated when clinical evaluation (including string check) is normal. TV‑US is warranted when clinical exam suggests malposition or when the IUD string is not visible or there is suspicion of incorrect position.prevalence abnormal position ~4–7.7%

Prospective study showed high NPV of clinical exam; imaging reserved for suspected malposition.

inv-06: Deep infiltrating endometriosis — diagnostic criteria

Diagnosis of deep infiltrating endometriosis (DIE)

TV‑US diagnostic performance for DIE: Transvaginal ultrasound demonstrates high sensitivity and specificity for detection of deep infiltrating endometriosis in multiple studies and pooled analyses; performance is operator- and technique-dependent, with excellent accuracy in experienced centers. MRI has comparable performance in many pelvic locations and may have higher specificity for some sites.pooled sensitivities/specificities vary by location (e.g., rectosigmoid sensitivity ~0.85, specificity ~0.96)

Site-specific performance and heterogeneity noted across studies; TV‑US often suitable as first-line imaging when expertise is available.

inv-07: DIE diagnosis

Diagnostic use for deep infiltrating endometriosis (DIE):

DIE detection modalities: Pooled analyses show similar diagnostic performance of TV‑US and MRI for detecting DIE involving rectosigmoid, uterosacral ligaments, and rectovaginal septum; pooled sensitivity and specificity vary by site and confidence intervals are wide, reflecting heterogeneity.

For rectosigmoid: TV‑US pooled sensitivity ~0.85 and specificity ~0.96; site-specific metrics vary.

inv-08: Cervical length assessment

Cervical length assessment to predict/prevent preterm birth:

Cervical length screening considerations: Routine universal transvaginal cervical length (TVU CL) screening is controversial. Measurement around 18–22 weeks is a useful screening test to predict spontaneous preterm birth. Women with cervical length ≤ 25 mm should have confirmatory TV‑US and review of risk factors and management options. TVU CL should be performed only when interventions to reduce preterm birth risk are available.≤25 mm

Evidence supports targeted measurement; universal screening utility remains debated.

inv-09: Embryo transfer guidance

TV‑US guidance during embryo transfer (ET):

ET guidance: Ultrasound-guided embryo transfer may improve clinical pregnancy and live-birth rates when catheter type is controlled; benefit is modest and should be balanced against cost and catheter type. Both ultrasound-guided transfer and clinical touch are acceptable approaches.

Evidence from systematic review: benefit seen when catheter type is the same across arms; overall effect depends on study methods.

inv-10: Vasa previa detection

Vasa previa diagnosis:

Vasa previa detection: Transvaginal ultrasound with color Doppler in the second trimester can detect vasa previa with high sensitivity and specificity in prospective studies. Close proximity of membranous fetal vessels to the internal cervical os (commonly defined as within ~2 cm) is considered abnormal and suggestive of vasa previa.within 2 cm of internal os

Prospective studies reported very high sensitivity and specificity when specifically sought.

inv-11: Ectopic pregnancy

Ectopic pregnancy diagnosis:

Ectopic pregnancy detection: Transvaginal ultrasound is the imaging modality of choice for suspected ectopic pregnancy. Single-exam detection rates vary (e.g., 76.5% in one series); sensitivity and specificity are high (initial sensitivity ~88.5%, specificity ~96.5%) and improve with repeat scanning (sensitivity ~93.1%, specificity ~95.7%). Diagnosis relies on integration of serial hCG testing and TV‑US findings.

Repeat scanning and experienced operators improve diagnostic performance.

inv-12: Pelvic congestion syndrome

Pelvic congestion/pelvic vein incompetence:

Pelvic congestion syndrome evaluation: Transvaginal ultrasound with Doppler and magnetic resonance venography are useful noninvasive screening tests for pelvic vein incompetence, but accuracy data are limited. Specific sonographic findings reported include pelvic vein >5 mm crossing the uterine body (specificity ~91 %) and pelvic varicoceles (sensitivity 100 %, specificity 83–100 %). Venography remains the reference standard; positioning and maneuvers (upright, Valsalva) affect sensitivity.

Methodological limitations noted; further research needed.

inv-13: Diagnosis of Ectopic Pregnancy

Supporting statements about TV‑US utility in ectopic pregnancy diagnosis

Ectopic pregnancy TV‑US diagnostic performance: TV‑US is the imaging modality of choice for suspected ectopic pregnancy: initial sensitivity 88.5% and specificity 96.5%, improving with repeat scan to sensitivity 93.1% and specificity 95.7%. Diagnosis is clinical, combining serial hCG testing and TV‑US; imaging should be performed by clinicians experienced in gynecologic ultrasound when possible.

Data from retrospective analyses and tertiary center series.

inv-14: Diagnosis of Pelvic Congestion Syndrome (PCS)

Role of ultrasound and MRI in PCS work‑up

PCS imaging: Noninvasive tests (TV‑US with Doppler, transabdominal US, and MRI) have shown adequate sensitivity in some studies compared with venography. Findings include pelvic vein >5 mm crossing the uterine body (specificity ~91 %) and pelvic varicoceles (sensitivity 100 %, specificity 83–100 %). Venography remains the gold standard; ultrasound sensitivity may be reduced with supine positioning and improved with upright or Valsalva maneuvers.

Study quality and methodological diversity limit definitive conclusions.

inv-15: Evaluation of Inguinal and Extra‑pelvic Endometriosis

Findings and diagnostic considerations for inguinal/extra‑pelvic endometriosis

Inguinal endometriosis suspicion: Consider inguinal endometriosis in reproductive‑age women presenting with an inguinal mass and cyclic pain or size changes; prevalence among endometriosis cases is low (~0.3–0.6%). Ultrasound is often of limited assistance for preoperative diagnosis while MRI may show characteristic findings. Definitive diagnosis typically requires histology after surgical excision; fine-needle aspiration cytology is diagnostic but rarely used.

High clinical suspicion and multidisciplinary evaluation recommended; surgical excision is standard management.

inv-16: Evaluation of Pelvic Pain

Use of TV‑US in pelvic pain assessment

Pelvic pain imaging: Transvaginal and transabdominal ultrasound are first-line imaging for suspected gynecologic causes of pelvic pain. Color Doppler is standard and spectral Doppler is added when torsion is a concern. CT or MRI may be used based on the differential diagnosis. TV‑US may cause discomfort in some postmenopausal women (reported ~26.8%).

Choice of imaging should be guided by a narrowed differential diagnosis and clinical context.

When a transvaginal ultrasound (TV‑US) is performed on pelvic structures located within the bony pelvis, an abdominal or pelvic ultrasound performed by an abdominal approach is considered duplicative and does not warrant separate reimbursement. The policy states that pelvic echography using an abdominal approach is clinically integral to the transvaginal exam and should not be billed separately in those cases.

Routine population‑based screening of asymptomatic women for ovarian or endometrial cancer with TV‑US is not supported by current evidence. Randomized trials and systematic reviews have not demonstrated a mortality benefit from routine screening with TV‑US (alone or with biomarkers), and professional bodies have concluded there is insufficient evidence to recommend routine population screening. For women at elevated genetic risk (e.g., Lynch II), TV‑US may be used for monitoring, but general annual screening in asymptomatic populations is not recommended.

Society reviews and trials have found insufficient evidence to support routine universal transvaginal cervical length screening in low‑risk pregnant women. Cervical length measurement can be useful in selected populations and when linked to management pathways, but routine screening of asymptomatic, low‑risk women is not indicated per current evidence summaries.

In the excerpted portions of the policy there are no additional explicit exclusions beyond those noted elsewhere (for example, duplicative abdominal pelvic ultrasound and specific non‑covered screening encounter codes).

This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is intended to assist in administering plan benefits. It is not a contract and does not guarantee coverage or results; coverage determinations may vary by specific plan and provider contract.

For monitoring women with Lynch II syndrome, the policy notes that use of Doppler ultrasound mode (TV‑DUS) is not medically necessary. Although Doppler can add information about tumor vascularity, the policy states this mode is not required for routine surveillance in this population.

Annual transvaginal ultrasound screening of asymptomatic women for ovarian or endometrial cancer is not supported by evidence demonstrating a mortality benefit. Large randomized trials and systematic reviews have not established benefit from routine annual TV‑US screening in the general population; therefore, routine annual TV‑US for asymptomatic women is not recommended outside of defined high‑risk or research settings.

Within the provided excerpt there are no specific procedures or conditions explicitly labeled as not medically necessary beyond those already noted (for example, Doppler for Lynch II surveillance and routine population screening). The document does not list additional not‑medically‑necessary items in this section.

Examples of covered CPT codes referenced in the policy include 76817 (transvaginal ultrasound, pregnant uterus) and 76830 (transvaginal ultrasound, non‑obstetrical). These codes are listed as covered when the selection/medical necessity criteria in this policy are met.

Coding and Billing Guidance

Covered CPT Codes (examples shown)CPTCovered

76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal.
76830	Ultrasound, transvaginal (non-obstetrical) [except for confirmation of placement of an intrauterine device following insertion].

Other related CPT CodesCPT

76801	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation.
76802	Each additional gestation (List separately in addition to code for primary procedure).
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete.
76857	Limited or follow-up (eg, for follicles).

ICD-10 Codes covered if selection criteria are met (not all-inclusive)ICD-10Covered

C53.0-C55	Malignant neoplasm of uterus.
C56.1-C56.9	Malignant neoplasm of ovary.
C79.60-C79.63	Secondary malignant neoplasm of ovary.
D25.0-D25.9	Leiomyoma of uterus [fibroid].
D27.0-D27.9	Benign neoplasm of ovary.
N95.0	Postmenopausal bleeding.
N97.0-N97.9	Female infertility.
O00.00-O00.91	Ectopic pregnancy.
Q51.0-Q51.5,Q51.810-Q51.818,Q51.9	Congenital malformations of uterus.
Z15.02	Genetic susceptibility to malignant neoplasm of ovary [Lynch II syndrome (BRCA2 mutation)].

ICD-10 Codes not covered for indications listed in the CPBICD-10Not Covered

Z01.411-Z01.419	Encounter for gynecological examination (general) (routine).
Z12.73	Special screening for malignant neoplasms of ovary.
Z12.79	Encounter for screening for malignant neoplasm of other genitourinary organs [endometrium].
Z30.431	Encounter for routine checking of intrauterine contraceptive device.
Z97.5	Presence of (intrauterine) contraceptive device.

Endometrial thickness (postmenopausal bleeding)

Endometrial thickness threshold<= 4 mm — when TV-US shows endometrial thickness ≤4 mm in a patient with postmenopausal bleeding, endometrial sampling is not required (triage threshold)

Action when >4 mmIf endometrial thickness >4 mm on TV‑US in postmenopausal bleeding, additional assessment (eg, endometrial sampling) is usually indicated

Initial test optionsEither endometrial biopsy OR TV‑US may be used as the initial evaluation for postmenopausal bleeding; both are not required

Cervical length (short cervix) thresholds

Short cervix threshold≤ 25 mm — women with cervical length ≤25 mm (typically measured at 14–28 weeks) should have confirmatory TV‑US and review of risk/management options

Timing of measurementSingle cervical length measurement around 18–22 (or 18–24) weeks is commonly used to predict spontaneous preterm birth

Confirmatory testingWomen with cervical length <25 mm should undergo a subsequent transvaginal ultrasound to confirm the finding before management decisions

Vasa previa — proximity criterion

Vasa previa proximity thresholdWithin 2 cm of the internal cervical os — membranous fetal vessels in close proximity (≈≤2 cm) to the internal os are considered abnormal

Diagnostic methodPrenatal diagnosis is based on identification of membranous fetal vessels crossing or in close proximity to the internal os by real‑time TV‑US with color Doppler

Clinical implicationVasa previa increases risk of vessel rupture with potential fetal hemorrhage; transvaginal color Doppler in 2nd trimester shows high sensitivity in studies

Provider Actions, Prior Authorization, and Documentation

Denial Risk

TV‑US for population ovarian cancer screening

TV‑US is not recommended for routine population screening for ovarian cancer. Large randomized screening trials and systematic reviews show high rates of surgery per detected cancer and no established mortality benefit; use TV‑US only for symptomatic evaluation or in high‑risk surveillance when clinically indicated.

Do not perform TV‑US for asymptomatic population screening for ovarian cancer.
Consider TV‑US when women present with persistent (>3 weeks) symptoms suggestive of ovarian cancer and after pelvic and rectal exam.

Billing Rule

Avoid duplicate abdominal/pelvic ultrasound

When TV‑US is performed, pelvic (abdominal) ultrasound is considered clinically integral to the transvaginal exam; performing both approaches on the same patient when pelvic structures are within the bony pelvis is duplicative and does not warrant separate reimbursement.

Avoid billing pelvic (abdominal) ultrasound separately if a TV‑US is performed on pelvic structures within the bony pelvis (duplicative).
TV‑US provides superior detail for pelvic structures and is the preferred approach when appropriate.

Prior Authorization

Prior authorization

Prior authorization requirements are not specified in this excerpt of the CPB. Check payer-specific prior authorization resources or medical policy portals for any local PA programs that may apply.

No PA requirements listed in this CPB excerpt — verify with Aetna prior authorization tools if needed.
When in doubt, obtain PA per member plan terms before elective scheduling.

Prior Authorization

Prior authorization and codes

This document provides CPT codes that are commonly used for TV‑US (e.g., 76817, 76830). The CPB does not list any CPT/HCPCS codes that explicitly require prior authorization in the provided excerpt; however, non-covered diagnosis codes listed below may trigger claim denial if used as the indication.

Covered TV‑US CPT codes when selection criteria are met: 76817 (transvaginal obstetrical), 76830 (transvaginal non‑obstetrical).
Other related CPTs: 76856, 76857 (pelvic ultrasound complete/limited).
Confirm payer coding guidance for PA linkage to specific CPTs (76817, 76830) if local PA policies exist.

Denial Risk

Not‑covered diagnosis codes may trigger denial

Certain ICD‑10 screening or routine encounter codes are not covered for the indications in this CPB and may trigger denial if billed as the primary indication for TV‑US.

Not‑covered ICD‑10 codes for the CPB indications include: Z01.411‑Z01.419 (gynecological exam, routine), Z12.73 (special screening for malignant neoplasms of ovary), Z12.79 (screening for other genitourinary organs), Z30.431 (routine IUD check), Z97.5 (presence of IUD).
Avoid using screening encounter codes as primary diagnosis when performing TV‑US for diagnostic indications.

Documentation Required

Initial test selection

For evaluation of post‑menopausal bleeding (PMB) either endometrial biopsy or TV‑US may be used as the initial test; performing both routinely as the first step is not required. If TV‑US demonstrates endometrial thickness >4 mm in PMB, further assessment such as endometrial sampling is indicated.

Initial acceptable approaches for PMB: endometrial biopsy or TV‑US (either alone as initial test).
If TV‑US endometrial thickness ≤4 mm, endometrial sampling typically not required; if >4 mm, pursue additional evaluation.

Step Therapy

Step therapy

No step therapy requirements are described in this CPB excerpt.

Step therapy not applicable based on provided text.

Documentation Required

Quality/training documentation

Quality assurance and training standards are available for certain TV‑US measurements (e.g., cervical length). Practitioners performing cervical length measurements should follow recognized quality programs such as CLEAR and Perinatal Quality Foundation standards.

Consider completion of CLEAR program or equivalent for cervical length measurement competency and documentation.
Document training and image review completion as applicable for quality assurance.

Note

Providers are responsible for medical advice

Treating providers are responsible for medical advice and treatment of members. The CPB is informational, assists in administering plan benefits, and does not guarantee coverage or substitute clinical judgment.

Providers retain responsibility for clinical decision‑making and patient counseling.
Use the CPB to inform benefit administration but rely on clinical judgment and payer‑specific coverage determination.

Note

None specified in this excerpt / Provider action placeholder

No additional provider actions, prior authorization triggers, or explicit documentation requirements are specified in this excerpt beyond the items above. Verify local Aetna plan resources for any member‑specific or regional requirements.

If a plan requires PA or has specific documentation expectations, follow that plan's published processes.
This CPB does not replace payer contract language; consult Aetna provider portals for operational details.

Definitions

Transvaginal ultrasonography (TV‑US) — definition & uses

DefinitionTransvaginal ultrasonography (TV‑US) — endovaginal ultrasound using a high‑frequency probe inserted into the vagina to provide detailed views of pelvic structures

Primary clinical usesEvaluation of pelvic masses, endometrial thickness, infertility monitoring, IUD localization, ectopic pregnancy, pelvic pain, and guidance for embryo transfer

AdvantagesCloser proximity of probe yields superior resolution of pelvic organs with less interference from bowel gas or adipose tissue compared with transabdominal US

Transvaginal Doppler ultrasonography (TV‑DUS)

DefinitionTransvaginal Doppler ultrasonography (TV‑DUS) — TV‑US mode that adds Doppler assessment (color and/or spectral) to evaluate vascularity

Policy positionUse of Doppler mode is considered not medically necessary for TV‑US monitoring of women with Lynch II syndrome (per policy note)

Utility noteTV‑DUS may improve distinction between benign and malignant adnexal lesions in some studies, but impact on patient management is unclear

Lynch syndrome (definition)

DefinitionLynch syndrome — autosomal‑dominant hereditary non‑polyposis colorectal cancer syndrome caused by germline mutation in DNA mismatch repair genes

Cancer riskAssociated with substantially increased lifetime risk of endometrial cancer (≈40–60%) and other cancers

Screening recommendationsGuidelines include annual endometrial sampling and TV‑US beginning at age ~30–35 years for affected women

Vasa previa — definition

DefinitionVasa previa — obstetric complication in which fetal vessels lie outside the chorionic plate in close proximity to the internal cervical os, risking vessel rupture and fetal hemorrhage

DetectionPrenatal detection uses real‑time TV‑US with color Doppler to identify membranous fetal vessels crossing or near the internal os

Clinical importancePrenatal diagnosis permits management to reduce risk of fetal death or serious morbidity

Cervical length (TVU CL) — definition & relevance

DefinitionCervical length (TVU CL) — sonographic measurement of the cervix by transvaginal ultrasound used to assess risk of spontaneous preterm birth

Short cervix relevanceA short cervix (commonly defined as ≤25 mm) identifies women at increased risk for spontaneous preterm birth and should prompt confirmation and review of management options

Measurement timingSingle measurement between ~18–24 weeks (often at fetal anatomic survey) is commonly used; confirmatory repeat TV‑US is recommended if ≤25 mm

TV‑US — short definition

Short definitionTV‑US — ultrasound exam using a high‑frequency endovaginal probe inserted into the vagina to image pelvic organs with high resolution

Common componentsTypically includes gray‑scale imaging and color Doppler; spectral Doppler added when indicated (eg, torsion)

Role in careFirst‑line imaging for many gynecologic and early obstetric indications due to detailed visualization and wide availability

Pelvic congestion syndrome (PCS)

DefinitionPelvic congestion syndrome (PCS) — condition associated with pelvic vein dilatation/incompetence and chronic pelvic pain

Diagnostic gold standardVenography is the current gold standard diagnostic test for PCS

Noninvasive testingTV‑US with Doppler and MRI have shown adequate sensitivity in some studies (eg, vein >5 mm crossing uterine body specificity ~91%), but evidence is limited

Inguinal endometriosis

DefinitionInguinal endometriosis — rare localization of endometriotic tissue in the inguinal canal or round ligament presenting as an inguinal mass often with cyclic pain

Prevalence and presentationExtremely rare (≈0.3–0.6% of endometriosis cases); presents as an inguinal swelling with cyclic pain and often requires high clinical suspicion

Diagnosis and managementDefinitive diagnosis usually requires histology after surgical excision; MRI may be helpful; FNAC is occasionally diagnostic

Clinical Policy Bulletin — definition & scope

DefinitionClinical Policy Bulletin — Aetna's summary guidance developed to assist in administering plan benefits; not a contract or direct medical advice

ScopeProvides clinical policy guidance on medical necessity, investigational uses, limitations, and coding for TV‑US

Coverage noteCPBs contain only a partial description of plan benefits; coverage determinations may vary by plan and this document does not guarantee coverage

OpenPayer

Transvaginal Ultrasonography (TV‑US)

Coverage and Medical Necessity Criteria

Coding and Billing Guidance

Provider Actions, Prior Authorization, and Documentation

Background and Rationale

Definitions